Johnson & Johnson停止开发Genmab的多种骨髓瘤药物GEN3014,援引发展问题。 Johnson & Johnson halts development of Genmab's multiple myeloma drug, GEN3014, citing development issues.

Johnson & Johnson(J&J)不会继续研制Genmab的药物HexaBody-CD38(GEN3014)并进行商业化, Johnson & Johnson (J&J) will not pursue the development and commercialization of Genmab's drug HexaBody-CD38 (GEN3014) for multiple myeloma, leading Genmab to halt its further clinical development despite initial promising data. Genmab的首席执行官表示信任该公司开发中的其他抗体疗法,包括EPKINLYZ和两个阶段3的资产。 Genmab's CEO expressed confidence in the company's other antibody therapeutics in development, including EPKINLY® and two Phase 3 assets. 这项决定不影响Genmab的2025年财务前景。 This decision does not affect Genmab's 2025 financial outlook.